|Mr. August J. Moretti J.D., Esq.||CFO & Sr. VP||611.34k||71.74k||66|
|Mr. Matthew M. Gosling||Sr. VP, Gen. Counsel & Sec.||712.74k||N/A||46|
|Mr. Arthur Joseph Higgins||CEO, Pres & Director||N/A||N/A||61|
|Ms. Sharon D. Larkin||Sr. VP of HR & Admin.||N/A||N/A||53|
|Mr. Christopher S. Keenan||VP of Investor Relations and Corp. Communications||N/A||N/A||N/A|
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. The company sells its products to wholesalers and retail pharmacies. It also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Depomed, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 2; Compensation: 6.